Medincell Reports Significant Growth in UZEDY® Sales

Medincell, in partnership with Teva Pharmaceuticals, announced a strong performance for its U.S.-marketed product UZEDY®, with net sales reaching $85 million in Q3 2026. This marks a 96% increase compared to the previous year. In the first nine months of 2026, UZEDY® achieved $225 million in sales, already surpassing the full-year revenue for 2025.

As a result, Teva has adjusted its 2026 revenue outlook for UZEDY®, raising it to $290-310 million. The treatment, a risperidone long-acting injectable, has grown rapidly in the market, supported by enhanced hospital access and a wider prescriber base, adding over 800 new prescribers monthly.

Medincell earns royalties from UZEDY® sales and could receive up to $105 million in milestone payments. The product is part of Medincell's broader strategy to offer long-acting treatments, with a similar olanzapine product, WELTRUZA™, set to launch in the U.S later in 2026.